替格瑞洛与氯吡格雷对急性冠状动脉综合征患者PCI术后的疗效比较

详细信息    查看全文 | 推荐本文 |

英文篇名：Therapeutic effect of ticagrelor versus clopidogrel on patients with acute coronary syndrome after percutaneous coronary intervention 作者：曹清野 ; 张桂珍 英文作者：CAO Qing-ye;ZHANG Gui-zhen;Yongcheng Central Hospital; 关键词：替格瑞洛 ; 氯吡格雷 ; 急性冠状动脉综合征 ; 冠状动脉介入手术 英文关键词：Ticagrelor;;Clopidogrel;;Acute coronary syndrome;;Coronary artery interventional surgery 中文刊名：YYSO 英文刊名：Chronic Pathematology Journal 机构：永城市中心医院; 出版日期：2019-05-15 出版单位：慢性病学杂志 年：2019 期：v.20 基金：河南省科技厅重点攻关项目(142102310396) 语种：中文; 页：YYSO201905010 页数：3 CN：05 ISSN：11-5900/R 分类号：30-32

摘要

目的对比替格瑞洛和氯吡格雷对急性冠状动脉综合征经皮冠状动脉介入术(PCI)术后患者的疗效。方法选取2016年1月至2017年1月80例永城市中心医院就诊的急性冠状动脉综合征PCI术后患者,随机分为观察组和对照组,每组40例。观察组给予替格瑞洛治疗,对照组给予氯吡格雷治疗。对比两组PCI术后1个月两组血小板功能、炎性因子变化及不良反应发生情况。结果治疗后,观察组的血小板最大聚集率及G蛋白偶联嘌呤受体(P2Y12)反应单位水平均低于对照组(P<0.05)。对照组的超敏C反应蛋白及内皮素-1水平均高于观察组(P<0.05),一氧化氮水平低于观察组(P<0.05)。治疗后观察组微出血及支架内再狭窄发生例数低于对照组(P<0.05)。结论对急性冠状动脉综合征患者PCI术后采用替格瑞洛治疗,可有效抑制血小板聚集及炎症反应强度,且不良反应少。
        Objective To compare the efficacy of ticagrelor and clopidogrel in the treatment of patients with acute coronary syndrome after percutaneous coronary intervention(PCI). Methods Totally 80 patients with acute coronary syndrome after PCI in Yongcheng Central Hospital from January 2016 to January 2017 were randomly divided into the observation group and the control group, 40 cases in each group. The observation group was treated with ticagrelor, while the control group was treated with clopidogrel. The platelet function, inflammatory factors and adverse reactions were compared between the two groups one month after PCI. Results After treatment, the maximum platelet aggregation rate and the level of P2 Y12 reaction unit levels in the observation group were lower than those in the control group(all P<0.05). The levels of hypersensitive C-reactive protein and endothelin-1 in the control group were higher(P<0.05), and the level of nitric oxide was lower when compared to those in the observation group(P<0.05). After treatment, the incidence of microbleeding and restenosis in stent in the observation group was lower than that in the control group(P<0.05). Conclusion Ticagrelor can effectively inhibit platelet aggregation and inflammation in patients with acute coronary syndrome after PCI, and has less adverse reactions.

引文

[1]孙喜文,张灿,林秋伟.替格瑞洛在急性冠脉综合征患者介入治疗中的应用效果[J].中国循证心血管医学杂志,2017,9(1):102-104.
    [2]贾珠银,瞿小丹,孙家驹,等.替格瑞洛对非ST段抬高急性冠状动脉综合征患者冠状动脉微循环的影响[J].中国介入心脏病学杂志,2016,24(5):256-260.
    [3]李文铮,李世英,吴铮,等.替格瑞洛对非ST段抬高急性冠状动脉综合征经皮冠状动脉介入治疗围术期高敏C反应蛋白和短期预后的影响[J].中国介入心脏病学杂志,2015,23(5):265-268.
    [4]王丽双,温福兴.替格瑞洛联合氯吡格雷对急性冠脉综合征患者经皮冠状动脉介入术后微血管功能的影响[J].实用心脑肺血管病杂志,2017,25(S2):83-84.
    [5]金春,宋颖,祖武,等.替格瑞洛与氯吡格雷对急性冠状动脉综合征患者经皮冠状动脉介入术后不良心脏事件的影响[J].疑难病杂志,2017,16(5):433-436.
    [6]陈英,杨军,曹佳宁,等.在对急性冠状动脉综合征患者进行经皮冠状动脉介入治疗中应用替格瑞洛与氯吡格雷的价值对比[J].当代医药论丛,2017,15(21):116-117.
    [7]张玉惠,刘俊,陈金国,等.替格瑞洛与氯吡格雷对急性冠状动脉综合征患者血小板聚集的对比分析[J].蚌埠医学院学报,2016,41(6):733-735,738.